혈우병 치료 시장 : 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The global hemophilia treatment market size is expected to reach USD 28.08 Billion in 2034 from USD 17.14 Billion in 2025, growing at a CAGR of 5.64 during 2026-2034.The global hemophilia treatment market is growing steadily due to the increasing diagnosis of hemophilia and rising awareness about early treatment. Hemophilia, a genetic bleeding disorder, requires lifelong management, which has led to sustained demand for effective therapies. Improved healthcare infrastructure and greater availability of diagnostic tools have also contributed to the growing number of diagnosed patients, supporting market expansion across both developed and emerging economies.

Advancements in biotechnology and pharmaceutical research have significantly improved treatment options for hemophilia patients. The introduction of recombinant clotting factors, extended half-life therapies, and non-factor replacement therapies has enhanced treatment outcomes and reduced the frequency of injections. In addition, increasing investments by pharmaceutical companies and research institutions are accelerating the development of innovative therapies aimed at improving patient quality of life.

In the future, the hemophilia treatment market is expected to benefit from the rapid progress of gene therapy and personalized medicine approaches. Gene-based treatments have the potential to offer long-term or even curative solutions for patients, transforming the treatment landscape. Increasing healthcare expenditure and improved access to specialized treatment centers are also expected to drive continued market growth globally.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease Type

• Hemophilia A
• Hemophilia B
• Other disease types

By Product

• Recombinant coagulation factor concentrates
• Plasma-derived coagulation factor concentrates
• Extended half-life products
• Desmopressin
• Antifibrinolytic agents
• Gene therapy products

By Patient

• Pediatric
• Adult

By Treatment

• Prophylaxis
• On demand

By Therapy

• Factor replacement therapy
• Non-factor replacement therapy

By Drug Class

• Vasopressin
• Coagulation factors

By Route of Administration

• Injectable
• Nasal spray
• Oral

By End-use

• Hospitals
• Clinics
• Hemophilia treatment centers
• Other end-users

COMPANIES PROFILED

• Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc., Biotest AG, CSL Behring LLC, Ferring B.V., Genentech Inc., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi SA, Swedish Orphan Biovitrum AB (Sobi), Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEMOPHILIA TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Disease Type
• 4.2. Hemophilia A Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Hemophilia B Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Other disease types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEMOPHILIA TREATMENT MARKET: BY PRODUCT 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Product
• 5.2. Recombinant coagulation factor concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Plasma-derived coagulation factor concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Extended half-life products Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Desmopressin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Antifibrinolytic agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Gene therapy products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEMOPHILIA TREATMENT MARKET: BY PATIENT 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Patient
• 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEMOPHILIA TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Treatment
• 7.2. Prophylaxis Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. On demand Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HEMOPHILIA TREATMENT MARKET: BY THERAPY 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Therapy
• 8.2. Factor replacement therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Non-factor replacement therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HEMOPHILIA TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 9.1. Market Analysis, Insights and Forecast Drug Class
• 9.2. Vasopressin Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 9.3. Coagulation factors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL HEMOPHILIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 10.1. Market Analysis, Insights and Forecast Route Of Administration
• 10.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.3. Nasal spray Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 10.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL HEMOPHILIA TREATMENT MARKET: BY END-USE 2022-2034 (USD MN)

• 11.1. Market Analysis, Insights and Forecast End-use
• 11.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.4. Hemophilia treatment centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 11.5. Other end-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL HEMOPHILIA TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

• 12.1. Regional Outlook
• 12.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.2.1 By Disease Type
  • 12.2.2 By Product
  • 12.2.3 By Patient
  • 12.2.4 By Treatment
  • 12.2.5 By Therapy
  • 12.2.6 By Drug Class
  • 12.2.7 By Route Of Administration
  • 12.2.8 By End-use
  • 12.2.9 United States
  • 12.2.10 Canada
  • 12.2.11 Mexico
• 12.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.3.1 By Disease Type
  • 12.3.2 By Product
  • 12.3.3 By Patient
  • 12.3.4 By Treatment
  • 12.3.5 By Therapy
  • 12.3.6 By Drug Class
  • 12.3.7 By Route Of Administration
  • 12.3.8 By End-use
  • 12.3.9 United Kingdom
  • 12.3.10 France
  • 12.3.11 Germany
  • 12.3.12 Italy
  • 12.3.13 Russia
  • 12.3.14 Rest Of Europe
• 12.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.4.1 By Disease Type
  • 12.4.2 By Product
  • 12.4.3 By Patient
  • 12.4.4 By Treatment
  • 12.4.5 By Therapy
  • 12.4.6 By Drug Class
  • 12.4.7 By Route Of Administration
  • 12.4.8 By End-use
  • 12.4.9 India
  • 12.4.10 Japan
  • 12.4.11 South Korea
  • 12.4.12 Australia
  • 12.4.13 South East Asia
  • 12.4.14 Rest Of Asia Pacific
• 12.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.5.1 By Disease Type
  • 12.5.2 By Product
  • 12.5.3 By Patient
  • 12.5.4 By Treatment
  • 12.5.5 By Therapy
  • 12.5.6 By Drug Class
  • 12.5.7 By Route Of Administration
  • 12.5.8 By End-use
  • 12.5.9 Brazil
  • 12.5.10 Argentina
  • 12.5.11 Peru
  • 12.5.12 Chile
  • 12.5.13 Rest of Latin America
• 12.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 12.6.1 By Disease Type
  • 12.6.2 By Product
  • 12.6.3 By Patient
  • 12.6.4 By Treatment
  • 12.6.5 By Therapy
  • 12.6.6 By Drug Class
  • 12.6.7 By Route Of Administration
  • 12.6.8 By End-use
  • 12.6.9 Saudi Arabia
  • 12.6.10 UAE
  • 12.6.11 Israel
  • 12.6.12 South Africa
  • 12.6.13 Rest of the Middle East And Africa

Chapter 13. COMPETITIVE LANDSCAPE

• 13.1. Recent Developments
• 13.2. Company Categorization
• 13.3. Supply Chain & Channel Partners (based on availability)
• 13.4. Market Share & Positioning Analysis (based on availability)
• 13.5. Vendor Landscape (based on availability)
• 13.6. Strategy Mapping

Chapter 14. COMPANY PROFILES OF GLOBAL HEMOPHILIA TREATMENT INDUSTRY

• 14.1. Top Companies Market Share Analysis
• 14.2. Company Profiles
  • 14.2.1 Bayer AG
  • 14.2.2 Biogen Inc
  • 14.2.3 BioMarin Pharmaceutical Inc
  • 14.2.4 Biotest AG
  • 14.2.5 CSL Behring LLC
  • 14.2.6 Ferring B.V
  • 14.2.7 Genentech Inc
  • 14.2.8 Kedrion S.p.A
  • 14.2.9 Novo Nordisk A/S
  • 14.2.10 Octapharma AG
  • 14.2.11 Pfizer Inc
  • 14.2.12 Sanofi SA
  • 14.2.13 Swedish Orphan Biovitrum AB (Sobi)
  • 14.2.14 Takeda Pharmaceutical Company Limited